Answer First
Semaglutide is a mono-agonist that targets the GLP-1 receptor only. Tirzepatide is a dual agonist, activating both the GLP-1 receptor and the GIP receptor. Retatrutide is a triple agonist, activating GLP-1, GIP, and glucagon (GCG) receptors. Each represents a progressively broader receptor engagement profile in the published literature, and each is studied as a distinct compound — not as interchangeable variants of the same mechanism.
Receptor targets: the core distinction
The single most important difference between these three peptides is which receptors they engage. Researchers use this table as a quick reference when designing comparative protocols.
| Receptor | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| GLP-1R (glucagon-like peptide-1 receptor) | Agonist | Agonist | Agonist |
| GIP-R (glucose-dependent insulinotropic polypeptide receptor) | Not targeted | Agonist | Agonist |
| GCG-R (glucagon receptor) | Not targeted | Not targeted | Agonist |
| Receptor count | 1 (mono-agonist) | 2 (dual agonist) | 3 (triple agonist) |
This receptor progression is why the three compounds are often studied as a class series rather than as substitutes for one another. Adding GIP receptor activity in tirzepatide, and then glucagon receptor activity in retatrutide, changes the downstream signaling pathways being investigated — not just the magnitude of a single pathway.
Pharmacokinetics: half-life, dosing, and molecular profile
All three are long-acting analogs engineered for infrequent dosing in research protocols, achieved through amino acid substitutions and, in most formulations, a fatty acid or fatty diacid moiety that promotes albumin binding and slows clearance.
| Property | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Reported half-life | ~7 days | ~5 days | ~6 days |
| Dosing interval reported in published studies | Weekly | Weekly | Weekly |
| Approximate molecular weight | 4,113.6 g/mol | 4,813.5 g/mol | 4,731.4 g/mol |
| Sequence backbone origin | Modified native GLP-1 (37 amino acids) | Engineered dual-receptor peptide (39 amino acids) | Engineered triple-receptor peptide (39 amino acids) |
| Year first characterized in literature | ~2012 | ~2013 | ~2020 |
The half-life differences are modest across the class — published studies for all three report a once-weekly dosing interval in the study protocols reviewed. Reported half-life figures vary somewhat between studies depending on formulation, assay method, and study population, so any single number should be treated as an approximation rather than a fixed constant. This is a summary of the published literature, not usage instructions; Sequence Labs sells these compounds strictly for laboratory and in-vitro research use, not for human or animal administration.
Where each compound sits in the research literature
Published research on each compound clusters around different focus areas, reflecting both their receptor profile and their relative time in the literature.
- Semaglutide has the deepest and longest-running body of literature of the three, with published research spanning GLP-1 receptor signaling, appetite-regulation pathways, and metabolic markers in preclinical and clinical models.
- Tirzepatide literature focuses heavily on comparative dual-agonism, examining how combined GLP-1/GIP receptor activity differs from GLP-1 mono-agonism in metabolic and body-composition research endpoints.
- Retatrutide is the newest compound in this comparison, and its literature is smaller but growing quickly, with early published trials concentrating on triple-agonist receptor pharmacology and dose-ranging characterization.
Researchers selecting between these compounds for a given protocol should match the choice to receptor targets, not to assumptions about relative potency carried over from mainstream reporting.
Lyophilized storage: general lab handling
All three compounds ship as lyophilized powder. General laboratory best practices for lyophilized peptides — reconstitution under sterile/aseptic laboratory conditions, cold-chain storage, and light protection — apply as with any research peptide. Facility-specific reconstitution and storage protocols should follow your institution's or lab's own standard operating procedures and biosafety guidelines; Sequence Labs does not provide dosing, administration, or self-preparation instructions, and none of this content is intended as guidance for human or animal use.
Side-by-side summary
| Factor | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Mechanism class | GLP-1 mono-agonist | GLP-1/GIP dual agonist | GLP-1/GIP/GCG triple agonist |
| Literature depth | Extensive | Substantial, growing | Emerging |
| Dosing interval reported in published studies | Weekly | Weekly | Weekly |
| Common research focus | Metabolic signaling, appetite pathways | Comparative dual-receptor effects | Triple-receptor pharmacology, dose-ranging |
| Available at Sequence Labs | Yes — product page | Yes — product page | Yes — product page |
Frequently asked questions
What's the difference in receptor activity between semaglutide, tirzepatide, and retatrutide?
Semaglutide activates only the GLP-1 receptor. Tirzepatide activates GLP-1 and GIP receptors. Retatrutide activates GLP-1, GIP, and glucagon receptors. This receptor count is the primary pharmacological distinction between the three compounds.
Which has the longest half-life?
Semaglutide is generally reported with the longest half-life of the three, at approximately 7 days, compared to roughly 5 days for tirzepatide and 6 days for retatrutide. Published studies on all three report a once-weekly dosing interval in their study protocols; this reflects the literature, not a recommendation for use.
Which compound is most-studied?
Semaglutide has the largest and longest-running published literature base of the three, having been characterized earliest. Tirzepatide's literature is substantial and expanding. Retatrutide, the newest of the three, has a smaller but rapidly growing set of published studies.
Are they interchangeable in research protocols?
No. Each compound engages a different combination of receptors and is associated with a distinct reported pharmacological profile in the literature. Substituting one for another changes the mechanistic question under study, so protocols should specify the exact compound required and verify identity against a batch-matched COA.
What purity should I look for?
Look for a third-party Certificate of Analysis showing HPLC purity of 98% or higher, mass spectrometry confirming the expected molecular weight, and a batch number that matches the vial label and is searchable in a public COA library.